论文部分内容阅读
目的:探讨益髓生血颗粒治疗珠蛋白生成障碍性贫血的作用机制。方法:观察20例患儿治疗前后血红蛋白(Hb)、红细胞(RBC)、网织红细胞计数(Ret)、胎儿血红蛋白(HbF)的改变;选取10例有效病例,通过实时荧光定量PCR技术探讨该药对珠蛋白生成障碍性贫血患者骨髓有核细胞SCF和c-kit基因表达的影响。结果:治疗后患者各项血液学参数均有改善;骨髓有核细胞c-kit基因表达明显升高,与治疗前比较差异有显著性(P<0.05);SCF基因表达无明显改变。结论:益髓生血颗粒可以明显改善患者的临床症状,通过SCF/c-kit信号传导途径,调节红系祖细胞及其它造血细胞的增殖和分化过程,来达到治疗目的。
Objective: To investigate the mechanism of Yisu Shengxue Granule in treating globin-induced anemia. Methods: The changes of hemoglobin (Hb), erythrocytes (RBC), reticulocyte count (RET) and fetal hemoglobin (HbF) in 20 children before and after treatment were observed. Ten valid cases were selected and the drug was investigated by real-time fluorescence quantitative PCR Effect of SCF and c-kit gene expression on bone marrow nucleated cells in patients with thalassemia. Results: All the hematological parameters were improved after treatment. The expression of c-kit gene in bone marrow nucleated cells was significantly higher than that before treatment (P <0.05), while the expression of SCF gene did not change significantly. Conclusion: Yisui Shengxue Granule can significantly improve the clinical symptoms of patients, through the SCF / c-kit signaling pathway, regulating erythroid progenitor cells and other hematopoietic cells proliferation and differentiation process to achieve the purpose of treatment.